Larix A/S Licenses OmniComm Systems' eClinical Solutions
Larix A/S Licenses OmniComm Systems' eClinical Solutions
FORT LAUDERDALE, Fla., July 2, 2012 (GLOBE NEWSWIRE) – OmniComm Systems, Inc (OTCBB:OMCM), announced that it has signed an agreement with Larix A/S to support their clinical research needs for a 5 year, 31 site study.
Larix, a full-service Clinical Research Organization (CRO) in Denmark offering assistance in all aspects of clinical trials, provides services within statistics, Data Management (DM), Clinical Research (CR), Pharmacovigilance (PV) and Data Monitoring Committees (DMCs) to pharmaceutical, biotechnology and medical device companies. This partnership will enable Larix to provide their customers with high quality products and services to manage complex clinical trials. Larix will utilize OmniComm's fully integrated eClinical suite, including Portal, Electronic Data Capture (EDC), and Clinical Data Management System (CDMS).
"Larix was looking for a system which could support paper, EDC and hybrid studies and which could live up to Larix's quality standards to ensure compliance with regulatory requirements. Furthermore, we wanted a solution that was attractive both from a user's point of view and from a cost point of view. We looked at several solutions but decided in the end to go with OmniComm's eClinical Suite. We believe that the system is flexible and easy to use. We are pleased with this collaboration between Larix and OmniComm." said Klaus Juel Olsen, CEO.
"We are pleased to have been chosen by this prestigious family founded CRO." said Stephen Johnson, President and COO of OmniComm. "They've become one of the largest Danish CROs based on their strong reputation for good customer service, and we look forward to partnering with them to build on their reputation for providing quality solutions and services."
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
